Thermo Fisher Scientific Inc. (TMO – Free Report) recently released the Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit, which is intended to safely collect saliva for research purposes. The new kit was introduced to support ongoing SARS-CoV-2 research efforts around the world, as laboratories increasingly use banked saliva samples to conduct scientific studies, taking advantage of a easy-to-access and non-invasive type of sample.
The SpeciMAX Stabilized Saliva Collection Kit is available for research purposes only and not for use in diagnostic procedures.
By management, SpeciMAX stabilized saliva collection kits are compatible with downstream automation workflows to help reduce costs and time for viral research.
Safer sample collection with the new kit
The SpeciMAX Stabilized Saliva Collection Kit promotes safer sample collection by preserving viral nucleic acids in a safe stabilizing solution that inactivates common respiratory viruses. The stabilized solution is non-hazardous, does not contain guanidinium to avoid interaction with bleach and is compatible with all disinfection protocols. For RNA and viral nucleic acid, the stabilizing agent preserves nucleic acid in saliva samples for up to 14 days at room temperature and up to two years for gDNA.
Image source: Zacks Investment Research
The kit includes a splash-resistant funnel, a screw cap to secure the sample after collection, as well as a standard-size tube that fits perfectly into automated viral RNA extraction workflows for the high throughput sample processing.
More on the news
The SpeciMAX stabilized saliva collection kit complements the recently launched SpeciMAX saliva collection kit for raw saliva. Both products are individually wrapped and provided with a barcode. These only require 1ml of saliva and are available in a standardized 6ml size to accommodate downstream automation workflows.
The SpeciMAX Stabilized Saliva Collection Kit consists of components manufactured under license from Isohelix, a division of Cell Projects Limited.
By a report published in Grand View Research, the size of the COVID-19 diagnostics market is expected to experience a CAGR of 3.1% from 2021 to 2027. Factors such as increase in government initiatives for mass testing, increase in cases of patients infected with coronavirus after the lockdown eased, greater traction achieved by the mobile testing market space and several testing programs to pave the way for the travel industry to prepare, are boosting the market.
Considering the market outlook, Thermo Fisher’s launch of the Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit to support global SARS-CoV-2 research efforts appears timely.
Thermo Fisher is embarking on a number of important developments this month.
The company introduced the first net zero mass spectrometer, which enables scientists in geoscience, food and beverage, environmental science, and forensic science to practice science in a more sustainable way. The new Thermo Scientific Delta Q Isotope Ratio Mass Spectrometer (“IRMS”) was launched as part of the IsoFootprint campaign to permanently eliminate carbon dioxide emissions from the manufacturing and supply chain of all new products Inorganic IRMS.
The company introduced the Thermo Scientific NanoDrop Eight UV-Vis Microvolume Spectrophotometer. Molecular biologists can use the NanoDrop Eight to measure the concentrations and purity of their biological samples, identify and correct contaminants, and differentiate DNA from RNA. The NanoDrop Eight replaces the NanoDrop 8000. It can evaluate eight samples simultaneously in 20 seconds or less, allowing academic and industrial researchers to analyze protein and nucleic acid samples faster and with more efficiency compared to NanoDrop 8000.
Share price return
The stock has outperformed its industry over the past year. It increased by 31.3% compared to the industry growth of 13.4%.
Zacks rank and choice of keys
Currently, Thermo Fisher wears a Zacks Rank # 3 (Hold).
Some top-ranked stocks in the medical device industry include Semler Scientifique inc. (SMLR – Free report), Alcon Inc. (YEARS – Free report) and IDEXX Laboratories, Inc. (IDXX – Free Report), each carrying a Zacks Rank # 2 (Buy). You can see The full list of today’s Zacks # 1 Rank (Strong Buy) stocks here.
Semler Scientific has a long-term profit growth rate of 25%.
Alcon has a long-term profit growth rate of 17.7%.
IDEXX has a long-term earnings growth rate of 19.9%.